Table 2 Virological and Biochemical Responses During ETV Rescue Therapy
From: Antiviral efficacy of entecavir for hepatitis B virus rtA181V/T mutants
Response | rtA181 group (n = 31) | rtA181 + rtN236 group (n = 25) | P value |
|---|---|---|---|
Virological | |||
HBV DNA Reduction (log10 IU/mL) | |||
6th Month (Mean ± SD) | 3.18 ± 1.92 | 3.52 ± 2.04 | 0.520 |
12th Month (Mean ± SD) | 3.59 ± 1.85 | 3.76 ± 2.15 | 0.756 |
undectectable | |||
6th Month (No. %) | 24/31 (77.4%) | 19/25 (76.0%) | 0.900 |
12th Month (No. %) | 27/31 (87.1%) | 22/25 (88.0%) | 0.919 |
HBeAg loss | |||
6th Month (No. %) | 3/24 (1.3%) | 1/18 (5.6%) | 0.448 |
12th Month (No. %) | 5/24 (20.8%) | 2/18 (11.1%) | 0.403 |
Biochemical | |||
Total bilirubin level (μmol/L) | |||
6th Month (Mean ± SD) | 16.0 ± 10.0 | 14.3 ± 4.7 | 0.440 |
12th Month (Mean ± SD) | 16.3 ± 8.9 | 14.4 ± 3.7 | 0.329 |
Normalization of serum Tbil | |||
6th Month (No. %) | 26/31 (%) | 22/25 (72.0%) | 0.661 |
12th Month (No. %) | 24/31 (89.6%) | 22/25 (88.0%) | 0.304 |
ALT (U/L) | |||
6th Month (Mean ± SD) | 38.3 ± 20.6 | 37.7 ± 15.0 | 0.903 |
12th Month (Mean ± SD) | 37.2 ± 18.4 | 34.3 ± 12.2 | 0.500 |
Normalization of serum ALT | |||
6th Month (No. %) | 23/31 (74.2%) | 21/25 (84.0%) | 0.374 |
12th Month (No. %) | 28/31 (90.3%) | 20/25 (80.0%) | 0.272 |